Aztreonam

證據等級: L5

預測適應症: 10 個

Aztreonam: From Gram-Negative Bacterial Infections to Gonococcal Urethritis

One-Sentence Summary

Aztreonam is a monobactam beta-lactam antibiotic with established clinical use against gram-negative aerobic bacterial infections, including urinary tract infections, lower respiratory tract infections, and septicemia. The TxGNN model predicts it may be effective for Gonococcal Urethritis, with 1 completed Phase 2/3 clinical trial and 8 publications currently supporting this direction. This prediction is mechanistically sound: Neisseria gonorrhoeae is a gram-negative organism directly susceptible to aztreonam's cell wall inhibition mechanism, and the repurposing is clinically urgent given the global rise of multidrug-resistant gonorrhea.

Quick Overview

Item	Content
Original Indication	Gram-negative bacterial infections (UTI, lower respiratory tract infections, septicemia, skin and skin-structure infections)
Predicted New Indication	Gonococcal Urethritis
TxGNN Prediction Score	99.59%
Evidence Level	L2
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Aztreonam is a monobactam antibiotic that selectively inhibits gram-negative bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP3). Unlike penicillins and cephalosporins, aztreonam possesses an exclusively gram-negative spectrum with no activity against gram-positive bacteria or anaerobes. This narrow but targeted selectivity makes it directly applicable to infections caused by gram-negative pathogens.

Currently, detailed mechanism of action data is not captured in this evidence pack. Based on well-established pharmacology, aztreonam is a monobactam (the only commercially available member of this antibiotic class), and its efficacy across gram-negative infections — including Escherichia coli, Klebsiella, Pseudomonas aeruginosa, and Haemophilus influenzae — has been proven in multiple registered indications. Neisseria gonorrhoeae, the causative agent of gonococcal urethritis, is a gram-negative diplococcus that expresses PBP3 as an essential target, making aztreonam mechanistically applicable.

The clinical urgency of this repurposing direction cannot be overstated. The WHO and US CDC have designated antimicrobial-resistant N. gonorrhoeae as an urgent public health threat. As strains with reduced susceptibility to ceftriaxone — currently the last reliable first-line therapy — continue to spread globally, aztreonam represents a clinically viable alternative or salvage option. Clinical evidence dates back to the 1980s, and a Phase 2/3 trial completed in 2019 (NCT03867734) confirmed eradication efficacy of single-dose intramuscular aztreonam 2 g for pharyngeal gonorrhea. However, emerging high-level aztreonam resistance in some gonococcal strains (documented as early as 2001) means local susceptibility surveillance is essential before routine deployment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03867734	Phase 2/3	Completed	32	Single-arm demonstration study of single-dose IM aztreonam 2 g for pharyngeal N. gonorrhoeae in men. Conducted April–September 2019 in the context of urgent AMR threat from N. gonorrhoeae exhausting available first-line antibiotics. Published results available (PMID 33077658).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33077658	2020	Phase 2/3 Clinical Trial	Antimicrobial Agents and Chemotherapy	Single-arm open-label trial; single-dose IM aztreonam 2 g evaluated for pharyngeal gonorrhea eradication in men; directly corresponds to NCT03867734; supports aztreonam as gonorrhea salvage therapy in ceftriaxone-resistant era
3157346	1985	Clinical Study	Antimicrobial Agents and Chemotherapy	Head-to-head comparison of aztreonam 1 g IM vs spectinomycin 2 g IM for uncomplicated gonorrhea; no treatment failures with either drug; effective at urethral, rectal, and endocervical sites
3095216	1986	Clinical Study	Genitourinary Medicine	87 patients (61 men, 26 women); single-dose aztreonam 1 g IM cleared N. gonorrhoeae at all sites except pharynx in one bisexual male; effective against both penicillin-sensitive and resistant strains; well tolerated
6438364	1984	Clinical Evaluation	Japanese Journal of Antibiotics	30 male patients with gonococcal urethritis; 61 N. gonorrhoeae strains tested (15% PPNG); bacteriological and clinical evaluation demonstrated aztreonam efficacy across both PPNG and non-PPNG strains
3937450	1985	Epidemiological/Therapeutic Study	Hinyokika Kiyo	Single-shot aztreonam therapy for gonorrheal infections; 244 clinical isolates evaluated (17.2% PPNG); epidemiological data showed predominantly younger patients; demonstrated broad clinical utility
6225808	1983	Prospective Clinical Study	Journal of Infectious Diseases	Early evaluation of aztreonam against penicillinase-producing N. gonorrhoeae (PPNG); demonstrated efficacy as an alternative when penicillin failed; important historical proof-of-concept
6226596	1983	Clinical Study	Giornale Italiano di Dermatologia	Clinical study of aztreonam in patients with acute gonococcal urethritis; early Italian evidence contributing to the broader efficacy profile
11406757	2001	Resistance Surveillance	Journal of Infection and Chemotherapy	Critical safety signal: emergence of cephem- and aztreonam-high-resistant N. gonorrhoeae without beta-lactamase; first documentation of high-level aztreonam resistance in gonococci; underscores need for susceptibility testing before use

Singapore Market Information

Aztreonam is currently not marketed in Singapore with zero registered products. Any clinical use in Singapore would require import authorization, hospital formulary exception, or compassionate use arrangement from the Health Sciences Authority (HSA).

Safety Considerations

Formal package insert warnings and contraindications are not available in this evidence pack. Please refer to the official prescribing information for complete safety data.

Based on the evidence collected:

Resistance risk: High-level aztreonam resistance in N. gonorrhoeae has been documented (PMID 11406757). Susceptibility testing is mandatory before use in this indication.
Drug Interactions: No DDI data was retrieved in this evidence pack.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Four decades of clinical data — culminating in a completed Phase 2/3 trial (NCT03867734) — establish aztreonam's efficacy against N. gonorrhoeae with a clear mechanistic basis. The global AMR gonorrhea crisis creates genuine unmet need, and aztreonam's repurposing is scientifically credible. However, drug unavailability in Singapore and the emergence of aztreonam-resistant gonococcal strains require careful pre-deployment assessment.

To proceed, the following is needed:

Local resistance surveillance: Obtain Singapore or regional (Southeast Asia) N. gonorrhoeae susceptibility data for aztreonam before any clinical deployment
Regulatory pathway: Initiate HSA consultation for import authorization or compassionate use, as aztreonam is not currently registered in Singapore
Dose clarification: Determine optimal regimen — historical studies used 1 g IM; the 2019 Phase 2/3 trial used 2 g IM for pharyngeal site; site-specific dosing guidance is needed
Combination strategy: Evaluate whether aztreonam should be used as monotherapy or combined (e.g., with azithromycin or doxycycline) to cover co-infections such as Chlamydia trachomatis
Full safety review: Obtain and parse the complete FDA/EMA prescribing information to document all contraindications and drug interactions before clinical protocol development
Pharmacokinetic consideration: Note that aztreonam has ~56% protein binding; PK parameters in relevant patient populations (e.g., patients with renal impairment) should be reviewed for dose adjustment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.